## Listing of claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Withdrawn) An isolated polynucleotide comprising a member selected from the group consisting of:
- (a) a polynucleotide having at least a 70% identity to a polynucleotide encoding a polypeptide comprising amino acids of SEQ ID NO:1;
  - (b) a polynucleotide which is complementary to the polynucleotide of (a); and
- (c) a polynucleotide comprising at least 15 bases of the polynucleotide of (a) or (b).
  - 2-9 (canceled).
- 10. (Withdrawn) A polypeptide comprising an amino acid sequence which is at least 70% identical to amino acid set forth in SEQ ID NO:1.
  - 11. (canceled).
  - 12. (Withdrawn) An agonist to the polypeptide of claim 10.
  - 13. (canceled).
- 14. (Withdrawn) An antagonist which inhibits the activity of the polypeptide of claim 10.
- 15. (Withdrawn) A method for the treatment of a patient having need of ICE-LAP 6 comprising: administering to the patient a therapeutically effective amount of the polypeptide of Claim 10.
  - 16. (canceled).
- 17. (Withdrawn) A method for the treatment of a patient having need to inhibit ICE-LAP 6 comprising: administering to the patient a therapeutically effective amount of the antagonist of Claim 14.
- 18. (Withdrawn) A process for diagnosing a disease or a susceptibility to a disease related to expression of the polypeptide of Claim 10 comprising: determining a mutation in the nucleic acid sequence encoding said polypeptide.
- 19. (Withdrawn) A diagnostic process comprising: analyzing for the presence of the polypeptide of Claim 10 in a sample derived from a host.

- 20. (Withdrawn) A method for identifying compounds which bind to and activiate or inhibit a receptor for the polypeptide of Claim 10 comprising: contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second component capable of providing a detectable signal in response to the binding of a compound to said receptor, with a compound to be screened under conditions to permit binding to the receptor; and determining whether the compound binds to and activates or inhibits the receptor by detecting the presence or absence of a signal generated from the interaction of the compound with the receptor.
- 21. (Previously Presented) An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:
  - (a) a protein consisting of amino acid residues 1 to 416 of SEQ ID NO:1;
  - (b) a protein consisting of amino acid residues 2 to 416 of SEQ ID NO:1;
- (c) a protein consisting of a portion of SEQ ID NO:1, wherein said portion consists of at least 30 contiguous amino acid residues of SEQ ID NO:1; and
- (d) a protein consisting of a portion of SEQ ID NO:1, wherein said portion consists of at least 50 contiguous amino acid residues of SEQ ID NO:1.
- 22. (Previously Presented) The antibody or fragment thereof of claim 21 that specifically binds protein (a).
- 23. (Previously Presented) The antibody or fragment thereof of claim 21 that specifically binds protein (b).
- 24. (Previously Presented) The antibody or fragment thereof of claim 21 that specifically binds protein (c).
- 25. (Previously Presented) The antibody or fragment thereof of claim 21 that specifically binds protein (d).
- 26. (Previously Presented) The antibody or fragment thereof of claim 22 that specifically binds protein (b).
- 27. (Currently Amended) The antibody or fragment thereof of claim 21, wherein
  Appl. Serial No.: 09/961,201

  4 Docket No. PF335D2

the antibody or fragment thereof which is a human antibody.

- 28. (Currently Amended) The antibody or fragment thereof of claim 21 which is a polyclonal antibody or a fragment of a polyclonal antibody.
- 29. (Currently Amended) The antibody or fragment thereof of claim 21 which is a monoclonal antibody or a fragment of a monoclonal antibody.
- 30. (Previously Presented) The antibody or fragment thereof of claim 21 which is selected from the group consisting of:
  - (a) a chimeric antibody;
  - (b) a humanized antibody;
  - (c) a single chain antibody; and
  - (d) an Fab fragment.
- 31. (Previously Presented) An isolated cell that produces the antibody or fragment thereof of claim 21.
- 32. (Currently Amended) A hybridoma that produces the antibody or fragment thereof-of claim 21.
- 33. (Withdrawn) A method of detecting an ICE-LAP 6 protein in a biological sample comprising:
- (a) contacting the biological sample with the antibody or fragment thereof of claim 21: and
  - (b) detecting the ICE-LAP 6 protein in the biological sample.
- 34. (Withdrawn) The method of claim 33 wherein the antibody or fragment thereof is a polyclonal antibody or a fragment of a polyclonal antibody.
- 35. (Currently Amended) An isolated antibody or fragment thereof, wherein the antibody has been obtained from an animal that has been immunized with a protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of amino acid residues 1 to 416 of SEQ ID NO:1;
- (b) the amino acid sequence of amino acid residues 2 to 416 of SEQ ID NO:1;
- (c) an amino acid sequence consisting of at least 30 contiguous amino acid residues of SEQ ID NO:1; and
- (d) an amino acid sequence consisting of at least 50 contiguous amino acid residues of SEQ ID NO:1;

wherein said antibody or fragment thereof specifically binds to said amino acid sequence.

- 36. (Previously Presented) The antibody or fragment thereof of claim 35 obtained from an animal immunized with protein (a).
- 37. (Previously Presented) The antibody or fragment thereof of claim 35 obtained from an animal immunized with protein (b).
- 38. (Previously Presented) The antibody or fragment thereof of claim 35 obtained from an animal immunized with protein (c).
- 39. (Previously Presented) The antibody or fragment thereof of claim 35 obtained from an animal immunized with protein (d).
- 40. (Currently Amended) The antibody or fragment thereof of claim 35 which is a monoclonal antibody or a fragment of a monoclonal antibody.
- 41. (Previously Presented) The antibody or fragment thereof of claim 35 which is selected from the group consisting of:
  - (a) a chimeric antibody;
  - (b) a polyclonal antibody;
  - (c) a humanized antibody;
  - (d) a single chain antibody; and
  - (e) an Fab fragment.

- 42. (Currently Amended) An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:
- (a) a protein consisting of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 975901095150;
- (b) a protein consisting of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number <u>975901095150</u>;
- (c) a protein consisting of a portion of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 975901095150, wherein said portion consists of at least 30 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 975901095150; and
- (d) a protein consisting of a portion of the polypeptide encoded by the cDNA contained in ATCC Deposit Number <u>975901095150</u>, wherein said portion consists of at least 50 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number <u>975901095150</u>.
- 43. (Previously Presented) The antibody or fragment thereof of claim 42 that specifically binds protein (a).
- 44. (Previously Presented) The antibody or fragment thereof of claim 42 that specifically binds protein (b).
- 45. (Previously Presented) The antibody or fragment thereof of claim 42 that specifically binds protein (c).
- 46. (Previously Presented) The antibody or fragment thereof of claim 42 that specifically binds protein (d).
- 47. (Currently Amended) The antibody or fragment thereof of claim 4243 that specifically binds protein (b).
- 48. (Currently Amended) The antibody or fragment thereof of claim 42, wherein the antibody or fragment thereof which is a human antibody.

- 49. (Currently Amended) The antibody or fragment thereof of claim 42 which is a polyclonal antibody or a fragment of a polyclonal antibody.
- 50. (Currently Amended) The antibody or fragment thereof of claim 42 which is a monoclonal antibody or a fragment of a monoclonal antibody.
- 51. (Previously Presented) The antibody or fragment thereof of claim 42 which is selected from the group consisting of:
  - (a) a chimeric antibody;
  - (b) a humanized antibody;
  - (c) a single chain antibody; and
  - (d) an Fab fragment.
- 52. (Previously Presented) An isolated cell that produces the antibody or fragment thereof of claim 42.
- 53. (Currently Amended) A hybridoma that produces the antibody or fragment thereof of claim 42.
- 54. (Withdrawn) A method of detecting ICE-LAP 6 protein in a biological sample comprising:
- (a) contacting the biological sample with the antibody or fragment thereof of claim 45; and
  - (b) detecting the ICE-LAP 6 protein in the biological sample.
- 55. (Withdrawn) The method of claim 54 wherein the antibody or fragment thereof is a polyclonal antibody or a fragment of a polyclonal antibody.
- 56. (Withdrawn) The method of claim 54 wherein the antibody or fragment thereof is a monoclonal antibody or a fragment of a monoclonal antibody.
- 57. (Currently Amended) An isolated antibody or fragment thereof, wherein the antibody has been obtained from an animal that has been immunized with a protein

comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 975901095150;

- (b) the amino acid sequence of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 975901095150;
- (c) an amino acid sequence consisting of at least 30 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 975901095150; and
- (d) an amino acid sequence consisting of at least 50 contiguous amino acid residues of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 975901095150;

wherein said antibody or fragment thereof specifically binds to said amino acid sequence.

- 58. (Previously Presented) The antibody or fragment thereof of claim 57 obtained from an animal immunized with protein (a).
- 59. (Previously Presented) The antibody or fragment thereof of claim 57 obtained from an animal immunized with protein (b).
- 60. (Previously Presented) The antibody or fragment thereof of claim 57 obtained from an animal immunized with protein (c).
- 61. (Previously Presented) The antibody or fragment thereof of claim 57 obtained from an animal immunized with protein (d).
- 62. (Currently Amended) The antibody or fragment thereof of claim 57 which is a monoclonal antibody or a fragment of a monoclonal antibody.
- 63. (Previously Presented) The antibody or fragment thereof of claim 57 which is selected from the group consisting of:
  - (a) a chimeric antibody;
  - (b) a polyclonal antibody;

- (c) a humanized antibody;
- (d) a single chain antibody; and
- (e) an Fab fragment.
- 64. (Previously Presented) An isolated antibody or fragment thereof that specifically binds an ICE-LAP 6 protein purified from a cell culture wherein said ICE-LAP 6 protein is encoded by a polynucleotide encoding amino acids 1 to 416 of SEQ ID NO:1 operably associated with a regulatory sequence that controls the expression of said polynucleotide.
- 65. (Currently Amended) The antibody or fragment thereof of claim 64 which is a monoclonal antibody or a fragment of a monoclonal antibody.
- 66. (Currently Amended) The antibody or fragment thereof of claim 64, wherein the antibody or fragment thereof which is a-human-antibody.
- 67. (Previously Presented) The antibody or fragment thereof of claim 64 which is selected from the group consisting of:
  - (a) a chimeric antibody;
  - (b) a polyclonal antibody;
  - (c) a humanized antibody;
  - (d) a single chain antibody; and
  - (e) an Fab fragment.
- 68. (Currently Amended) An isolated antibody or fragment thereof, wherein the antibody has been obtained from an animal that has been immunized with a protein comprising consisting of an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of amino acid residues <u>about 10</u> to <u>about 20</u> of SEQ ID NO:1;
- (b) the amino acid sequence of amino acid residues <u>about 40</u> to <u>about 50</u> of SEQ ID NO:1;
- (c) the amino acid sequence of amino acid residues <u>about 70</u> to <u>about 90</u> of SEQ ID NO:1; and

- (d) the amino acid sequence of amino acid residues <u>about 100</u> to <u>about 113</u> of SEQ ID NO:1;
- wherein said antibody or fragment thereof specifically binds to said amino acid sequence.
- 69. (Previously Presented) The antibody or fragment thereof of claim 68 obtained from an animal immunized with protein (a).
- 70. (Previously Presented) The antibody or fragment thereof of claim 68 obtained from an animal immunized with protein (b).
- 71. (Previously Presented) The antibody or fragment thereof of claim 68 obtained from an animal immunized with protein (c).
- 72. (Previously Presented) The antibody or fragment thereof of claim 68 obtained from an animal immunized with protein (d).
- 73. (Currently Amended) The antibody or fragment thereof of claim 68 which is a monoclonal antibody or a fragment of a monoclonal antibody.
- 74. (Previously Presented) The antibody or fragment thereof of claim 68 which is selected from the group consisting of:
  - (a) a chimeric antibody;
  - (b) a polyclonal antibody;
  - (c) a humanized antibody;
  - (d) a single chain antibody; and
  - (e) an Fab fragment.